scholarly journals Obesity and low levels of physical activity impact on cardiopulmonary fitness in older men after treatment for prostate cancer

Author(s):  
Sara Faithfull ◽  
Agnieszka Lemanska ◽  
Karen Poole ◽  
Jonathan Aning ◽  
Ralph Manders ◽  
...  
2017 ◽  
Vol 35 (5_suppl) ◽  
pp. 142-142
Author(s):  
Sara Faithfull ◽  
Jonathan Aning ◽  
Karen Poole ◽  
John Saxton ◽  
Bruce Griffin ◽  
...  

142 Background: Evidence from large observational studies suggests that men with prostate cancer have a higher risk of cardiovascular events due to accelerated atherosclerosis linked to androgen deprivation therapy (ADT). Adults > 70 years of age have poorer outcomes from cancer treatment in the UK. However, it is not yet clear what might be contributing to poorer outcomes among older men with prostate cancer. Thus the purpose of this study was to assess the health and fitness of a cohort of prostate cancer survivors, from 2 regions in the UK, and identify factors that may influence cardiovascular health. Methods: Baseline assessments from 83 men with prostate cancer with no evidence of distant disease particpated. Men undertook a Cardiopulmonary Exercise Test (CPET), sit to stand, step test, grip strength, hip to waist ratio, self-reported exercise questionnaire (Godin), and co-morbidity index. Men were 1-3 years post diagnosis. Age-group comparisons were made using analysis of covariance against cardiac risk profile (QRisk2). Results: Men who were older ( > 75) were more likely to have poorer cardiopulmonary fitness, as measured by VO2 Peak , and worse grip strength than age standardised values. Increased obesity across all groups (raised BMI) and higher B/P all contributed to a raised QRisk2 (mean: 36.9±6.1), which is higher than men of a similar age. Older men perceived themselves to be less physically active and were more likely to be on ADT. Conclusions: In our sample, men older than 75 had greater CVD risk, poorer physical function and lower strength. Improvements in diet and physical activity could improve physical function and reduce cardiovascular risk factors. Older men were more likely to be on ADT so to reduce long term co-morbidities other risk factors need to be addressed. More comprehensive functional health assessment at point of treatment could help clinicians optimise therapy to reduce long term comorbidities. [Table: see text]


2004 ◽  
Vol 4 (2-3) ◽  
pp. 102-106 ◽  
Author(s):  
d. m. flinton ◽  
n. j. walters

study objective: the study intended to investigate the possible relationship between physical activity and prostate cancer risk on a previously unexamined population set.design: a population-based study was conducted on males entered on the irish cancer registry between the years 1994 to 1997 to investigate if physical activity affected the risk of prostate cancer. activity was coded for three levels of occupational activity and the odds ratios were calculated together with 95% confidence limits.results: despite limitations in the data, an elevated risk (odds ratio 2.13, 95% confidence interval 1.29–3.52) was seen in working subjects with low levels of activity compared with the high activity group. in the retired group there was a slight elevation of risk, although it was not statistically significant.conclusion: the study suggests that physical activity offers a small but significant reduction in prostate cancer risk for those people in work.


Author(s):  
Agnieszka Lemanska ◽  
Karen Poole ◽  
Jonathan J. Aning ◽  
Bruce A. Griffin ◽  
Ralph Manders ◽  
...  

2013 ◽  
Vol 22 (04) ◽  
pp. 260-266 ◽  
Author(s):  
S. P. Tuck ◽  
R. M. Francis ◽  
B. C. Hanusch

SummaryMale osteoporosis is common and results in considerable morbidity and mortality. There are distinct differences in the normal aging of bone between the genders, which result in a lower fracture rate in men. Men who suffer from osteoporosis are much more likely than women to have secondary causes. The identification and treatment of these secondary causes, wherever possible, will result in substantial improvements in BMD. There is now evidence for use of many of the existing agents to treat osteoporosis in men. In younger hypogonadal men testosterone replacement is worth considering, but in older men especially the over sixties this is less effective and there is an increased risk of adverse cardiovascular and prostatic outcomes. Prostate cancer is an increasingly common cause, which is partially the result of the success of ADT. There is now good evidence for the use of bisphosphonates and denosumab in this group of patients. HIV, whilst not being specific to men, is an increasingly recognised cause of male osteoporosis. The reasons for this are multifactorial and some may well be attributable to the anti-retroviral therapy itself. There is emerging evidence of an increased fracture risk in HIV infected individuals. The bone loss can be prevented by the use of bisphosphonates.


Sign in / Sign up

Export Citation Format

Share Document